Logo

American Heart Association

  41
  0


Final ID:

Translating learning from traditional biomarker discovery to novel precision tools

  • Natarajan, Pradeep  ( Massachusetts General Hospital , Brookline , Massachusetts , United States )
  • Leopold, Jane  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
  • Author Disclosures:
    Pradeep Natarajan: DO have relevant financial relationships ; Researcher:Amgen, Genentech / Roche:Active (exists now) ; Other (please indicate in the box next to the company name):Vertex Pharmaceuticals (spousal employment):Active (exists now) ; Ownership Interest:Bolt, Candela, Mercury, MyOme, Parameter Health, Preciseli, TenSixteen Bio:Active (exists now) ; Consultant:Allelica, CRISPR Therapeutics, Genentech/Roche, HeartFlow, Magnet Biomedicine:Past (completed) ; Consultant:AstraZeneca, Blackstone Life Sciences, Bristol Myers Squibb, Eli Lilly & Co, Esperion Therapeutics, Foresite Capital, Foresite Labs, GV, Merck, Novartis, Novo Nordisk, TenSixteen Bio, Tourmaline Bio:Active (exists now) ; Researcher:Allelica, Novartis:Past (completed) | Jane Leopold: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

AI-enabled Risk Prediction in Cardiovascular Care

Monday, 11/10/2025 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
Risk scores to enable accessible precision care

Khan Sadiya, Coresh Josef

High dimensional genomics to inform practice

Taylor Casey, Hightower Maia, Bhatt Ami, Gupta Rajat

You have to be authorized to contact abstract author. Please, Login
Not Available